Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients. (Q34582940)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17854236%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

meta-analysis

0 references

title

Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17854236%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

0 references

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17854236%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

author name string

Juan Jose Perez-Ruixo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17854236%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Peter Zannikos

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17854236%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Sarapee Hirankarn

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17854236%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Kim Stuyckens

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17854236%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Elizabeth A Ludwig

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17854236%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Arturo Soto-Matos

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17854236%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Joel S Owen

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17854236%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

publication date

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17854236%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacokinetics

7 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17854236%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

volume

46

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17854236%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17854236%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

867-884

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17854236%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00003088-200746100-00005

7 January 2020

exact match

0 references

cites work

Hepatotoxicity and metabolism of trabectedin: a literature review.

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003088-200746100-00005

In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients

21 January 2018

1 reference

12 December 2020

Ecteinascidin-743 (ET-743): early test or effective treatment in soft tissue sarcomas?

1 reference

12 December 2020

Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma.

1 reference

12 December 2020

In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug

1 reference

12 December 2020

Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults

1 reference

12 December 2020

Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry

1 reference

12 December 2020

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours

1 reference

12 December 2020

A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study

1 reference

12 December 2020

Evaluation of Mixture Modeling with Count Data Using NONMEM

1 reference

12 December 2020

Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study

1 reference

12 December 2020

Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.

1 reference

12 December 2020

Molecular and crystal structures of ecteinascidins: potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinata

1 reference

12 December 2020

Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity

1 reference

12 December 2020

Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat

1 reference

12 December 2020

Improvement of the Cockcroft-Gault equation for predicting glomerular filtration in cancer patients.

1 reference

12 December 2020

Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment

1 reference

12 December 2020

The importance of modeling interoccasion variability in population pharmacokinetic analyses

1 reference

12 December 2020

A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion

1 reference

12 December 2020

Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity

1 reference

12 December 2020

Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.

1 reference

12 December 2020

A population pharmacokinetic model for docetaxel (Taxotere): model building and validation

1 reference

12 December 2020

Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis

1 reference

12 December 2020

A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

1 reference

12 December 2020

Induction of cytochrome P-450 by glucocorticoids in rat liver. II. Evidence that glucocorticoids regulate induction of cytochrome P-450 by a nonclassical receptor mechanism

1 reference

12 December 2020

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

1 reference

12 December 2020

Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.

1 reference

12 December 2020

Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743.

1 reference

12 December 2020

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

1 reference

12 December 2020

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

1 reference

12 December 2020

A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies

1 reference

12 December 2020

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma

1 reference

12 December 2020

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

1 reference

12 December 2020

Induction of cytochrome P-450 by glucocorticoids in rat liver. I. Evidence that glucocorticoids and pregnenolone 16 alpha-carbonitrile regulate de novo synthesis of a common form of cytochrome P-450 in cultures of adult rat hepatocytes and in the li

1 reference

12 December 2020

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

1 reference

12 December 2020

Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer.

1 reference

12 December 2020

Simple and sensitive liquid chromatographic quantitative analysis of the novel marine anticancer drug Yondelis (ET-743, trabectedin) in human plasma using column switching and tandem mass spectrometric detection

1 reference

12 December 2020

Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove

1 reference

12 December 2020